Introduction
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a propensity to transform to acute myeloid leukemia (AML). 1 AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. 2 Treatment outcomes of both MDS and AML are suboptimal. Outside the context of stem cell transplantation, MDS remains an incurable malignancy, and most patients with AML treated with chemotherapeutic regimens relapse and perish to their disease or associated complications. 3, 4 AML and MDS are typically diagnosed in elderly individuals (median age 65-70 years), and an intensive treatment approach can be applied only in the minority of patients owing to increased therapy-related mortality and decreased efficacy. [5] [6] [7] Thus, there is a great need for new agents with more benign toxicity profiles and improved activity for the treatment of MDS and AML. In recent years, drugs whose mechanism of action has been linked to modulation of gene transcription have taken center stage of both clinical and preclinical research in AML and MDS. 8 Histone deacetylase inhibitors (HDACIs) represent one class of gene expression modulating drugs, which is currently being developed for therapy of several types of cancer. 9 HDACIs were initially developed as putative epigenetic agents, owing to their ability to modify acetylation status of histones and induce gene expression. 10 Typically, optimal gene expression occurs when histones are in a state of maximal acetylation. 11 Therefore, HDACIs have the potential to cause re-expression of genes abnormally suppressed in cancer cells, thus potentially reversing the malignant phenotype and inducing growth inhibition, cellcycle arrest, differentiation and/or apoptosis. 9 However, more recent results of laboratory and clinical studies have indicated that besides modulation of gene expression, HDACIs have a diverse array of mechanisms of action, and the complexity of their effects on malignant cells has only begun to be unraveled. 9 HDACIs are being actively investigated as potential therapy of MDS and AML. Herein, we summarize the results of the most important clinical and preclinical studies with these drugs. 12 Histone modifications and transcriptional activity DNA is wrapped around the nucleosome, an octamer composed of two units of each of the main histones (H2A, H2B, H3 and H4), and forms a 'beads-on-a-string' structure, which folds into higher-order chromatin. 13 Chromatin structure modifications are important modulators of the transcriptional activity of specific genes. Post-transcriptional modifications of histones have an important role in changing the chromatin structure and thus modulating gene expression. 13 Covalent histone modifications include acetylation, methylation, phosphorylation, poly(ADP)-ribosylation and ubiquitination. 13 Certain modifications of specific amino-acid residues in histones lead to a more open chromatin configuration (euchromatin), which makes it more accessible to the transcription machinery, whereas other modifications change the chromatin into a more tightly wound structure (heterochromatin), which is associated with transcriptional silencing. 14, 15 It is believed that the combination of specific histone modifications constitutes a 'histone code' that determines the state of the chromatin and thus the transcriptional activity of genomic regions. 14 Acetylation is one of the main histone modifications associated with the regulation of gene expression. 15 Histones possess N-terminal tails that are rich in lysine. Acetylation of lysine residues opens the chromatin and promotes gene transcription, whereas histone deacetylation promotes chromatin condensation and represses gene transcription. 15 Histone deacetylation is mediated by histone deacetylases (HDACs). 15 HDACs are conventionally divided into families: class I, including the human HDACs 1, 2, 3 and 8; class II, which encompasses the human HDACs 5, 6, 7, 9 and 10; class III includes the NAD-dependent HDACs related to the yeast Sir2 protein (sirtuins); and class IV, defined by the recently identified human HDAC 11. 15, 16 Class I, II and IV HDACs are zinc (Zn 2 þ )-dependent enzymes and are considered the classical HDACs, distinctive from the unrelated sirtuins. 17 Available HDACIs only target the classical HDACs, whereas sirtuin inhibitors are currently under development. Besides histones, HDACs also have several other substrates, including transcription factors (for example, p53, signal transducer and activator of transcription 1 and 3), signaling mediators, steroid receptors, chaperone proteins (heat-shock protein 90 (Hsp90)) and DNA repair enzymes (Ku70). 18 Thus, a more appropriate name for these enzymes would be 'lysine deacetylases'. 18 
Histone deacetylase inhibitors
Increased activity of HDACs leading to reduced or abnormal histone acetylation patterns has been described in cancer cells. 19, 20 It has been shown that malignant cells present with higher level of HDACs than normal tissues, generating hypoacetylated histones. 20 Aberrant HDAC activity has also been described in certain leukemia subtypes that carry chimeric proteins resulting from translocations involving transcription factors such as core binding factor (t(8;21)(q22;q22)FAML1-ETO; inv(16)FCBFA-MYH11) and retinoic acid receptor alpha (RARA; t(15;17)(q24;q21)FPML-RARA). [21] [22] [23] [24] These chimeric proteins recruit HDACs to co-repressor complexes and block transcription of genes that lead to myeloid differentiation. Use of all-trans retinoic acid (ATRA) in patients with PML-RARApositive acute promyelocytic leukemia relieves the transcriptional blockade and impedes recruitment of HDACs, thus leading to cellular differentiation. 25 The development of HDACIs started with the discovery that several compounds that were known to induce differentiation of leukemic cell lines were inhibitors of HDACs and induced hyperacetylated histones. 10 This led to the development of other compounds with HDAC-inhibitory activity, based on the hypothesis that inhibition of HDACs would induce histone hyperacetylation and restore gene expression in cancer cells. This could potentially lead to cell differentiation, inhibition of proliferation and/or apoptosis. Many structurally diverse compounds can bind to HDACs and inhibit their enzymatic activity, including hydroxamates, cyclic peptides, aliphatic acids, benzamides and electrophilic ketones (Figure 1 ). They differ in their potency and specificity against different classes of HDACs ( Table 1) .
Mechanisms of action of HDACI
HDACIs exert a myriad of biological effects in cancer cells, including induction of differentiation/apoptosis, cell-cycle/mitotic arrest and induction of autophagic cell death (Figure 2) . 18 Normal cells seem to be resistant to cell death induced by HDACIs, and this selectivity could be exploited in the therapy of cancer patients. The mechanisms of action of HDACIs are complex, and to what extent the clinical activity of HDACIs is due to changes in transcription or effects on non-histone proteins is currently unknown and subject of much investigation.
HDACI can modify gene expression secondary to acetylation of histones and by altering the acetylation status of transcription factors and other proteins involved in transcription. 18 Microarray analyses of leukemic cell lines after exposure to HDACIs (trichostatin, vorinostat, romidepsin) have revealed modulation of a large number of genes (approximately 10-20% of the genome) repressing and inducing the expression of genes in equal measure. 26, 27 One of the more commonly HDACIinduced genes is the cyclin-dependent kinase (CDK) inhibitor CDKN1A (p21 WAF1/CIP1 ). [28] [29] [30] Induction of CDKN1A by vorinostat is p53 independent and accompanied by changes in the acetylation pattern of histones in the CDKN1A gene promoter. 28, 30 Increase in the level of p21 WAF1/CIP1 is linked to cell-cycle arrest which is observed upon exposure to HDACIs, but is not essential for HDACI-induced apoptosis. 31, 32 HDACIs also decrease the expression of cyclin proteins and CDKs and lead to hypophosphorylation of retinoblastoma protein, contributing to cell-cycle arrest. 33 Mitotic arrest and mitotic cell death in tumor cells is observed after exposure to HDACIs. HDACIs increase acetylation of histone H3K9 in pericentromeric chromatin, which interferes with assembly of the kinetochore. 34 This leads to mitotic arrest at prometaphase, followed by aberrant mitosis with chromosome segregation defects and eventually apoptosis/cell death. 35, 36 HDACIs can lead to cell death by activating apoptosis by both the intrinsic and the extrinsic pathways. HDACIs increase levels of the death receptor ligands FasL and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), as well as of death receptors Fas and DR5 in leukemic cells, indicating activation of the extrinsic apoptotic pathway. 32, 37 Upregulation of death receptors and their ligands is not observed in normal hematopoietic cells, indicating selectivity of these compounds for malignant cells. 32 Increased TRAIL expression is owing to increased acetylation of histones located at the TRAIL gene promoter and increased acetylation of the transcription factors Sp1 and Sp3, which stimulate the expression of TRAIL. 32 Interestingly, blocking TRAIL expression did not abrogate apoptosis in response to HDACIs in leukemic cells, indicating that additional mechanisms of apoptosis are responsible for cell death observed with these compounds. 32 Consistent with this contention, several studies have shown that HDACIs activate the intrinsic apoptotic pathway dependent on the mitochondria. HDACIs have been shown to increase levels of pro-apoptotic Bcl-2 family proteins (Bax, Bak, Bim, Bmf), [38] [39] [40] to downregulate antiapoptotic proteins (Bcl-2, Bcl-XL, MCL-1, XIAP, survivin) 38, 40, 41 and to enhance Bid cleavage and its subsequent activation. 42, 43 Exposure to HDACIs leads to increased cytoplasmic levels of cytochrome C and Smac, indicating mitochondrial injury and loss of mitochondrial membrane potential (Dcm). 41, 43 Increased expression of antiapoptotic Bcl-2 family proteins, such as Bcl-2, Bcl-XL and XIAP, has been associated with resistance to HDACI-induced apoptosis. 41, 44 HDACIs can cause DNA damage. HDACIs are known to sensitize cells to radiation and DNA-damaging chemotherapeutic agents, [45] [46] [47] and preclinical studies have shown that HDACIs induce phosphorylation of H2AX (g-H2AX) and ATM, which are markers of DNA damage. 48, 49 g-H2AX foci were located in the same chromatin strands as acetylated H3 and H4 histones. 48 Induction of DNA damage was followed by apoptosis with cleavage of caspase 3 and poly(ADP-ribose) polymerase. 48 Generation of g-H2AX foci in response to the HDACI LAQ-824 depends on increased generation of reactive oxygen species (ROS) (see below). 50 HDACI also contribute to DNA damage by impairing mechanisms of DNA repair, such as the non-homologous end-joining pathway for repair of DNA double-strand breaks. HDACIs have been shown to decrease levels of non-homologous end-joining proteins Ku80 and Rad50 and to decrease DNA binding of Ku70 by increasing its acetylation. 50, 51 Production of ROS may be an important mechanism in cell-death induced by HDACIs. 31, 41 Several HDACI (vorinostat, entinostat, LAQ-824) have been shown to increase intracellular ROS levels, 31, 41, 43 and HDACI's cytotoxicity is blocked by pre-exposure to antioxidants. 43 Exposure to the antioxidant N-acetylcysteine blocks mitochondrial injury and apoptosis induced by HDACIs in leukemic cells, suggesting that production of ROS is probably connected to activation of the mitochondrial death pathway. 31, 41 One recent report shows that vorinostat increases activity of the ROS-generating enzyme NADPH oxidase (NOX) in leukemic cell lines HL60, U937 and ML1, indicating that NOX is one of the major sources of increased ROS levels in vorinostat-treated cells. 52 Importantly, levels of the endogenous antioxidant thioredoxin are increased in response to HDACIs in normal cells compared with transformed cells, and no increase in ROS levels is observed in normal cells after exposure to vorinostat. 53 In contrast, HDACIs increase the expression of thioredoxin binding protein, a negative regulator of thioredoxin, in transformed cells, and this contributes to the observed increase in ROS levels. 53 Increase in ROS levels is followed by activation of an antioxidant response, which is one of the mechanisms of resistance to HDACIs. 52 Exposure of leukemic cells U937 to vorinostat leads to translocation of the transcription factor nuclear factor erythroid 2-like 2 (also known as Nrf2) to the nucleus, in which it transactivates its target genes. 52 Nrf2 is a master regulator of the antioxidant response, and it increases expression of several antioxidant genes, including GST (glutathione S-transferase), GSR (glutathione reductase), GCLC (glutathione synthase), SOD1 and SOD2 (superoxide dismutase 1 and 2), in response to vorinostat. 52 In a phase I clinical trial of vorinostat conducted in patients with AML/MDS, increased expression of 17 antioxidant genes (including TXN (thioredoxin), SOD1 and SOD2) correlated with resistance to vorinostat. 54 In addition, leukemic cells resistant to pan-HDACIs (HL-60/LR cells) display decreased production of ROS after exposure to the HDACI LAQ-824 in comparison to HDACI-sensitive cells. 44 After exposure to HDACIs, leukemic cells depend on the glutathione system to buffer increased levels of ROS, and depleting intracellular glutathione might be exploited to increase cellular sensitivity to HDACIs. 52 Combined exposure of vorinostat and the glutathione depleting compound phenylethyl isothiocyanate substantially increased the production of ROS and cytotoxicity in leukemic cells following exposure to vorinostat. 52 HDACI could be combined with other agents that generate ROS and cause DNA damage, such as anthracyclines (see below). In aggregate, these results suggest that HDACI-mediated apoptosis is, in part, dependent on the generation of ROS, with subsequent DNA and mitochondrial damage and activation of the intrinsic apoptotic pathway.
Inhibition of caspases does not completely prevent cell death induced by HDACIs such as vorinostat. 55 Caspase-independent cell death in response to HDACIs has morphological features of autophagic cell death. 55 Autophagy is a physiological cell death process characterized by the degradation of intracellular organelles by the lysosomal machinery. 56 Combination of HDACIs (MGCD0103 or vorinostat) with the BH3-mimetic compound GX15-070 induces both apoptosis and autophagy in leukemic cell lines and blasts from patients with AML, and inhibiting autophagy with chloroquine significantly increased cell viability, indicating that autophagy is an important mechanism of cell death in response to these drugs. 57 The ability of HDACIs to induce autophagy and caspase-independent cell death opens the door to the use of these compounds in the treatment of neoplastic cells bearing apoptotic defects.
Another potential mechanism of action of HDACI is blocking the activity of the chaperone protein Hsp90. 58 Chaperone proteins assist in the folding of client proteins and prevent their aggregation into non-functional structures and degradation by the proteasome. Hsp90 client proteins include several prosurvival proteins such as Bcr-Abl, FLT3, EGFR, VEFGR and Raf1. 58 Activity of Hsp90 is dependent on its acetylation status, with hyperacetylation abrogating Hsp90 function. 58, 59 The main HDAC responsible for removing acetyl residues from Hsp90 is the cytoplasmic HDAC6. Inhibition of HDAC6 leads to hyperacetylation and decreased activity of Hsp90, with consequent polyubiquitination and proteasomal degradation of its client proteins in leukemic cells. 58 Hsp90 antagonists (17-N-allylamino-17-demethoxy geldanamycin, 17-dimethylaminoethylamino-17-demethoxy-geldanamycin) are currently being developed and investigated in clinical trials of cancer patients, and there is potential for combining these compounds with HDACIs. 44 Development of resistance to HDACI is associated with increased expression of HDAC 1, 2 and 4, but decreased expression of HDAC6. 44 This leads to increased acetylation of Hsp90, and these cells show collateral sensitivity to Hsp90 inhibitors in vitro. 44 Thus, therapy with Hsp90 inhibitors might potentially over-ride resistance to HDAC inhibitors. 44 
Results of clinical trials with HDACIs
Several clinical trials are being conducted with HDACIs in patients with MDS and/or AML ( Table 2) . It is worth noting that most of the heretofore available information on HDACIs derives from phase I trials and is, therefore, preliminary. In general, single-agent HDACI therapy has been associated with low response rates, usually in the range of 10-20%. A common pattern of toxicity has been observed, with fatigue, nausea, vomiting and diarrhea being the most common dose-limiting toxicities (DLTs) with most HDACIs. Increases in histone acetylation have been detected by most studies, but no correlation with clinical responses has been established. There is rationale for utilizing HDACIs in combination with other agents, such as hypomethylating drugs and conventional chemotherapeutic agents. Several in vitro studies have revealed that HDACIs and DNA hypomethylating agents act synergistically to induce re-expression of silenced genes in cancer cells. 60 Several trials are currently exploring the clinical utility of such approach.
Valproic acid
Valproic acid (VPA, 2-propylpentanoic acid) is a short-chain fatty acid oral anticonvulsant that has been shown to induce differentiation of transformed hematopoietic progenitor cells and leukemic blasts from bone marrow and peripheral blood of patients with AML. 61 Besides its HDAC inhibitory activity, VPA also synergizes with ATRA in the differentiation induction of AML blasts in vitro. 62, 63 A phase I study of single-agent VPA rendered responses in 44% of patients with high-risk MDS and AML. 64 In a follow-up report from the same group, 75 patients with MDS (N ¼ 43) or AML (N ¼ 32) were treated with VPA, including nine patients who also received ATRA from the start of treatment. 65 Hematologic improvement (HI) was observed in 24% of patients, with higher response rates in those with MDS and normal blast counts (52%). The addition of ATRA did not improve response rates. Other studies using VPA either as single agent or in combination with ATRA as therapy of poor-risk AML/MDS have also reported minimal activity. [66] [67] [68] [69] Thus, it seems that the activity of single-agent VPA in MDS is mostly limited to patients with low-risk MDS and normal blast counts.
A phase I/II study evaluated the combination of VPA (escalating doses starting at 50 mg/kg orally daily for 7 days), 5-azacitidine (75 mg/m 2 for 7 days) and ATRA (45 mg/m 2 for 5 days, starting on day 3) in 53 patients with AML/MDS (relapsed/ refractory or untreated patients over 60 years of age). 70 The overall response rate (ORR) was 42%, including 12 patients (22%) with complete remissions (CR). The ORR in the subgroup of patients without previous therapy was 52%. The maximumtolerated dose (MTD) of VPA was 50 mg/kg, and DLTs were somnolence and confusion. Higher levels of VPA were found in responders compared with non-responders (132 versus 104 mg/ml; Po0.005). However, there was no correlation between VPA levels and histone acetylation or between histone acetylation and clinical responses.
VPA has also been combined with decitabine in two clinical studies. In the first report, 54 patients (AML ¼ 48; MDS ¼ 6) were treated with decitabine (15 mg/m 2 intravenously (i.v.) daily for 10 days) along with escalating doses of VPA (starting at 20 mg/kg) for 10 days. 71 The MTD of VPA was 50 mg/kg. The ORR was 22% (CR ¼ 19%; CR with incomplete platelet recovery ¼ 3%). Histone acetylation was detected in 35% of patients receiving VPA at the higher dose of 50 mg/kg. Transient DNA hypomethylation was observed and associated with reactivation of the CDKN2B gene. A preliminary analysis of an ongoing randomized phase II study evaluated the addition of VPA (50 mg/kg for 5 days) to therapy with decitabine (20 mg/m 2 i.v. for 5 days). 72 Seventy-four patients (AML ¼ 23; MDS ¼ 43; chronic myelomonocytic leukemia ¼ 8) were treated. The addition of VPA did not improve the ORR (52% (combination) versus 43% (single-agent decitabine), P ¼ nonsignificant (NS)) or time to response (57 days (combination) versus 64 days (single agent), P ¼ NS).
Vorinostat (suberoylanilide hydroxamic acid; SAHA; Zolinza)
Vorinostat is a potent HDACI containing a hydroxamic acid moiety that binds to the zinc-containing pocket in the catalytic site of HDAC1, 2, 3 and 6, causing their reversible inhibition. 73 Vorinostat is the first HDACI compound that was approved for the treatment of a malignant disease (primary cutaneous T-cell lymphoma). 74 Initial phase I studies of vorinostat in patients with lymphoma and solid tumors showed that the prolonged use of this drug was limited by the development of anorexia, vomiting, diarrhea, dehydration and fatigue, which typically occurred after 2 weeks of therapy and were reversible upon drug discontinuation. 75, 76 In a phase I study for patients with relapsed/refractory MDS or leukemia (AML ¼ 31; MDS ¼ 3; chronic lymphocytic leukemia ¼ 4; chronic myeloid leukemia ¼ 1; acute lymphoblastic leukemia ¼ 2), vorinostat was administered at two dose schedules: orally three times daily for 14 days every 21 days or orally twice daily for 14 days every 21 days. 54 The MTD was established at either 250 mg three times daily or 200 mg twice daily for 14 days every 21 days. DLTs were fatigue, nausea, vomiting and diarrhea. Overall, seven (17%) patients (all with AML) had a response: two CR, two CRi (CR with incomplete blood count recovery) and three HI. All patients who responded were receiving less than the MTD (100 mg/m 2 three times daily, 200 mg/m 2 three times daily and 200 mg/m 2 twice daily). Histone H3 acetylation was observed in all patients at all dose levels tested. Gene expression analysis revealed that the upregulation of ROS scavenger genes (see above) was associated with resistance to vorinostat, whereas downregulation of proliferation-associated genes was observed in patients who had clinical improvement. 54 If validated in a prospective manner, the predictive value of these gene expression signatures may allow for exclusion of non-responders from future clinical trials. In another study, 37 patients with AML were treated with vorinostat in a phase II trial, but only one patient had a clinical response. 77 Vorinostat was combined with 5-azacitidine in a phase I study. 78 Patients (MDS ¼ 20; AML ¼ 8) received different doses 
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Decitabine 20 mg/m 2 i.v. for 5 days+vorinostat 400 mg orally once daily (concomitantly or sequentially to decitabine) for 7-14 days 41% (concurrent); 21% (sequentially) Garcia-Manero et al. 82 
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Vorinostat 500 mg three times daily for 
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and vorinostat (200-300 mg orally, 2-3 times daily for 3-14 days). The ORR was 86% (CR 43%), and median time to response was two cycles. Main non-hematological toxicities were grade 1-2 fatigue and anorexia, which were more frequent with longer duration of vorinostat therapy (14 days). Vorinostat was also combined with decitabine in two independent phase I trials. In one study, 72 patients with AML/MDS received vorinostat (400 mg once daily, concomitant or following decitabine) and decitabine (20 mg/m 2 i.v. daily for 5 days). 79 The ORR (CR þ PR þ HI) was 41% in the concomitant schedule and 21% in the sequential schedule. Toxicity occurred in 89% of patients (most frequently grade 1-2 nausea, vomiting, fatigue, constipation and diarrhea) being severe in 24% of them. In another phase I trial, 31 patients with refractory/relapsed leukemia (including 21 with AML and three with MDS) received decitabine at escalating doses (10-25 mg/m 2 i.v. daily for 5 days) followed by vorinostat (100-200 mg orally three times daily for 2 weeks). 80 Only one patient achieved CR, whereas four others had reduction in bone marrow blasts. Adverse events included pulmonary embolism, diarrhea, neutropenia, fatigue, syncope and renal failure. The combination of vorinostat and hypomethylating agents (5-azacitidine or decitabine) appears active in high-risk MDS and AML. However, the ideal dose and schedule of vorinostat to be used in combination with these drugs still needs to be determined.
Preliminary evidence suggests that HDACIs are amenable to combination with standard chemotherapeutic agents. The activity of idarubicin has been evaluated in combination with vorinostat on the leukemia cell lines MOLT4 and HL60. 49 The combination of idarubicin with vorinostat at 0.075 mM resulted in at least an additive loss of viability in both cell lines. The combination of these agents increased histone H3 and H4 acetylation at 24 h, phosphorylated H2AX and induced CDKN2A mRNA. In another study, the leukemia cell lines HL60 and K562 were exposed to vorinostat, cytarabine and etoposide. 81 Concomitant use of vorinostat and cytarabine led to cytotoxic antagonism, whereas giving vorinostat first followed by a drug-free interval before cytarabine produced synergism. Etoposide given after vorinostat was also synergistic. Analyses of cell cycle revealed that vorinostat induces cell-cycle arrest in G1 or G2 phase, with subsequent recovery into the S phase after treatment is stopped, explaining the sequence-dependent synergism. Investigators at MD Anderson Cancer Center recently reported on the results of a phase II trial combining vorinostat with idarubicin and cytarabine in patients with AML. 82 Fifty-two patients with newly diagnosed AML received vorinostat (500 mg three times daily for 3 days) followed on day 4 by idarubicin (12 mg/m 2 /day for 3 days) and cytarabine (1.5 g/m 2 /day by continuous infusion for 4 days). Responding patients received five cycles of consolidation with the same dose of vorinostat, but reduced doses of idarubicin and cytarabine, followed by maintenance therapy with vorinostat (200 mg three times daily for 14 days, every 4 weeks, for 12 cycles). The CR rate was 80%, and no unexpected toxicities were observed. The median disease-free survival was 9.5 months and median overall survival has not been reached yet, but follow-up is short. The study is currently ongoing and a randomized trial is warranted to better define the value of adding vorinostat to standard induction chemotherapy in AML.
MGCD0103
MGCD0103 is an orally bioavailable sulfonamide anilide derivative isotype-specific HDACI, which targets isoforms 1, 2, 3 and 11. 83 In a dose escalation study, MGCD0103 was administered three times weekly to 29 patients with relapsed/ refractory leukemia or MDS and older patients with untreated AML or MDS. 84 The MTD was 60 mg/m 2 , with DLTs (fatigue, vomiting and diarrhea) observed at the dose level of 80 mg/m 2 . Dose-dependent histone acetylation occurred in all patients, and a maximal effect was seen at the 60 mg/m 2 dose level. Pharmacokinetics showed that drug exposure increased with subsequent doses up to 60 mg/m 2 . Two patients with relapsed/ refractory AML and one patient with MDS achieved a marrow CR (less than 5% blasts).
The combination of 5-azacitidine (75 mg/m 2 /day for 7 days) and MGCD0103 (escalating doses starting at 35 mg daily three times weekly, starting on day 5) was evaluated in a phase I/II trial in 57 patients with relapsed/refractory AML/MDS. 85 The ORR was 30% (11 out of 30 evaluable patients). The MTD of MGCD0103 in this trial was 90 mg three times weekly and observed DLTs included nausea, vomiting, diarrhea, anorexia and dehydration. A reduction in HDAC activity in peripheral blood mononuclear cells was observed in most treated patients.
Entinostat (MS-275)
Entinostat is a benzamide HDACI that has been shown to induce differentiation and apoptosis of human leukemia cells in vivo.
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In a phase I trial, entinostat was orally administered to 39 adults with advanced acute leukemia (AML ¼ 37; chronic myeloid leukemia-blast crisis ¼ 1; acute undifferentiated leukemia ¼ 1). 86 The MTD was defined as 8 mg/m 2 weekly for 4 weeks every 6 weeks. DLTs included neurological toxicity and laboratory abnormalities (hypertriglyceridemia and hyperglycemia). One patient had a CR in the bone marrow (blasts decreased from 54 to 3% in the first cycle) and three other patients had partial response in the bone marrow with temporary decreases in blasts counts, but no responses by AML International Working Group response criteria were observed. 87 Entinostat induced histone H3/H4 acetylation, CDKN1A expression and caspase-3 activation in bone marrow mononuclear cells.
A combined study of 5-azacitidine and entinostat was conducted in patients with AML (N ¼ 14), MDS (N ¼ 13) and chronic myelomonocytic leukemia (N ¼ 4). 88 Patients received entinostat (2-8 mg/m 2 on days 3 and 10) and 5-azacitidine (30-50 mg/m 2 subcutaneous on days 1-10). Responses were seen in 44% of patients, including 7.5% CR. DLTs were observed with entinostat at 8 mg/m 2 (laryngeal edema, prolonged neutropenia, fatigue). Fatigue was common with entinostat doses of 6 mg/m 2 , which precluded prolonged therapy. DNA methylation analysis of four different tumor suppressor genes (CDKN2B, CDH1, DAPK1 and SOCS1) conducted during the first cycle of therapy revealed that reversal of DNA promoter methylation was observed both in responders and non-responders. Similarly, increases in histone H3/H4 acetylation were observed in 92% of patients, with no correlation to clinical responses. 89 
Panobinostat (LBH589)
Panobinostat is a cinnamic hydroxamic acid analog that has potent activity as a HDACI and has been shown to induce apoptosis in AML cell lines. 90 Panobinostat was evaluated in a phase I study involving 15 patients (AML ¼ 13; MDS ¼ 1; acute lymphoblastic leukemia ¼ 1). 91 Patients received panobinostat as a 30-min i.v. infusion on days 1 to 7 every 21 days. Reversible grade 3 QTc prolongation was observed in four patients at 11.5 mg/m 2 . The median acetylation of histones H2B and H3 in CD34 þ blasts and B cells significantly increased on therapy as did apoptosis in CD14 þ cells. 91 No clinical responses were observed other than transient reductions in peripheral blood blasts.
Romidepsin (FK228; depsipeptide)
Romidepsin is a cyclic tetrapeptide derivative that is converted to its active conformation after being reduced intracellularly. 92 Romidepsin selectively inhibits HDAC isotypes 1, 2, 4 and 6. 93 Romidepsin was recently approved for treatment of primary cutaneous T-cell lymphoma. 94 In a phase I trial, romidepsin was administered at a dose of 13 mg/m 2 on days 1, 8 and 15 of a 28-day cycle to patients with AML (n ¼ 10) and chronic lymphocytic leukemia (n ¼ 10). 95 There was increased H3 histone acetylation at 4 h in all five patients analyzed, but no clinical responses were achieved. Development of progressive fatigue and nausea precluded repeated treatment.
Other HDACIs
Several more specific and potent HDACI are undergoing different stages of preclinical and/or clinical development (Table 1 ). For many of these novel agents, clinical data are either unavailable or still very preliminary. Similar to panobinostat, LAQ824 and PXD101 are hydroxamic acid derivatives with potent in vitro and in vivo antineoplastic activity that are currently being explored in clinical studies. 96, 97 Future perspectives Although promising, the precise role of HDACIs in the therapy of MDS/AML remains to be defined. Overall, the use of HDACIs used as single agents in patients with these malignancies yields modest results. Yet, selected patients appear to derive significant benefit from these compounds. Indeed, some patients achieve CR after having failed several lines of therapy and/or having become refractory to conventional chemotherapeutic agents. On the basis of available data, it appears that combinations of HDACIs with active agents in MDS such as DNA methylation inhibitors (that is, azacitidine or decitabine) or even with conventional cytotoxic chemotherapy may enhance the antileukemic activity of the latter. To further improve the clinical activity of HDACIs, two critical aspects of HDACI therapy warrant further investigation: (1) the exact mechanisms by which HDACIs work remain unclear. Although gene expression modulation is generally accepted as an important mechanism of action of HDACIs, a large variety of transcription factors and transcriptional co-regulators are modified by acetylation. HDACIs have been shown to induce CDKN1A expression, a key mediator of the tumor suppressor activity of p53 and appear to also alter the regulation of the tumor suppressor activity of the retinoblastoma protein. A better understanding of the in vivo mechanisms of action of HDACIs against leukemic cells will facilitate the development of combination strategies with novel agents, which, like Hsp90 antagonists or CDK inhibitors, hold great promise for the treatment of MDS and AML; (2) clinical evidence indicates that not all patients will benefit from HDACI therapy. It will therefore be important to identify reliable biomarkers such as specific gene signatures associated with response to better discern which patients will benefit the most from HDACI therapy. The enrollment of patients in clinical trials of HDACIs will certainly aid to answer these questions and to define the potential of these agents for the treatment of MDS and AML.
